Table 3. HRs of patients with different high-risk factors.
| Variables | HR (95% CI) | ||||||
|---|---|---|---|---|---|---|---|
| A1 | A2 | A3 | B1 | B2 | B3 | C | |
| Overall cohort | |||||||
| A1 | 1 | 0.31 (0.3–0.32)a | 0.33 (0.32–0.34)a | 0.41 (0.38–0.44)a | 0.38 (0.36–0.4)a | 0.16 (0.16–0.17)a | 0.21 (0.19–0.22)a |
| A2 | 3.72 (3.43–4.03)b | 1 | 1.06 (1.02–1.09)a | 1.31 (1.23–1.4)a | 1.21 (1.16–1.27)a | 0.52 (0.5–0.54)a | 0.66 (0.62–0.7)a |
| A3 | 4.05 (3.78–4.33)b | 1.09 (1.02–1.17)b | 1 | 1.24 (1.17–1.32)a | 1.15 (1.11–1.19)a | 0.49 (0.47–0.51)a | 0.62 (0.59–0.66)a |
| B1 | 3.44 (3.04–3.9)b | 0.93 (0.82–1.05)b | 0.85 (0.76–0.96)b | 1 | 0.93 (0.86–0.99)a | 0.4 (0.37–0.43)a | 0.5 (0.46–0.54)a |
| B2 | 5.29 (4.91–5.7)b | 1.42 (1.32–1.53)b | 1.31 (1.23–1.39)b | 1.54 (1.36–1.74)b | 1 | 0.43 (0.41–0.45)a | 0.54 (0.51–0.58)a |
| B3 | 11.6 (10.74–12.53)b | 3.12 (2.89–3.38)b | 2.87 (2.68–3.06)b | 3.37 (2.98–3.82)b | 2.19 (2.04–2.36)b | 1 | 1.27 (1.19–1.34)a |
| C | 10.95 (10–11.99)b | 2.95 (2.69–3.23)b | 2.71 (2.49–2.93)b | 3.19 (2.79–3.63)b | 2.07 (1.9–2.26)b | 0.94 (0.86–1.03)b | 1 |
| Cohort with LTs | |||||||
| A1 | 1 | 0.39 (0.38–0.42)a | 0.35 (0.34–0.37)a | 0.45 (0.42–0.49)a | 0.38 (0.36–0.4)a | 0.09 (0.08–0.09)a | 0.23 (0.21–0.24)a |
| A2 | 2.48 (2.23–2.76)b | 1 | 0.9 (0.85–0.94)a | 1.15 (1.05–1.26)a | 0.97 (0.91–1.02)a | 0.32 (0.3–0.35)a | 0.57 (0.53–0.62)a |
| A3 | 3.46 (3.19–3.75)b | 1.4 (1.26–1.54)b | 1 | 1.28 (1.18–1.4)a | 1.08 (1.03–1.13)a | 0.35 (0.33–0.37)a | 0.64 (0.59–0.69)a |
| B1 | 2.99 (2.55–3.51)b | 1.2 (1.02–1.43)b | 0.86 (0.74–1.01)b | 1 | 0.84 (0.77–0.92)a | 0.3 (0.26–0.34)a | 0.5 (0.45–0.55)a |
| B2 | 5.05 (4.62–5.51)b | 2.03 (1.83–2.26)b | 1.46 (1.35–1.58)b | 1.69 (1.44–1.98)b | 1 | 0.46 (0.42–0.49)a | 0.59 (0.55–0.64)a |
| B3 | 9.16 (8.27–10.15)b | 3.69 (3.28–4.16)b | 2.65 (2.41–2.91)b | 3.07 (2.59–3.63)b | 1.82 (1.64–2.01)b | 1 | 1.13 (1.04–1.23)a |
| C | 9.82 (8.74–11.04)b | 3.96 (3.48–4.51)b | 2.84 (2.55–3.17)b | 3.29 (2.76–3.92)b | 1.95 (1.74–2.18)b | 1.07 (0.95–1.22)b | 1 |
a, OS; b, PCSS. A1: T3–4, PSA ≤20 ng/mL, GS 2–7; A2: T1–2, PSA >20 ng/mL, GS 2–7; A3: T1–2, PSA ≤20 ng/mL, GS 8–10; B1: T3–4, PSA >20 ng/mL, GS 2–7; B2: T3–4, PSA ≤20 ng/mL, GS 8–10; B3: T1–2, PSA ≥20 ng/mL, GS 8–10; C: T3–4, PSA >20 ng/mL, GS 8–10. HR, hazard ratios; CI, confidence interval; LT, local treatment; OS, overall survival; PCSS, prostate cancer-specific survival; PSA, prostate-specific antigen; GS, Gleeson score.>20 ng/mL, GS 2–7; B2: T3–4, PSA ≤20 ng/mL, GS 8–10; B3: T1–2, PSA ≥20 ng/mL, GS 8–10; C: T3–4, PSA >20 ng/mL, GS 8–10. OS, overall survival; PCSS, prostate cancer-specific survival; CI, confidence interval; LT, local treatment.